Navigation Links
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Date:12/5/2007

mation is intended to enhance an investor's overall understanding of the company's past financial performance and prospects for the future. For example, non-GAAP earnings per share information is an indication of the company's baseline performance before items that are considered by the company to be not reflective of the company's ongoing results. In addition, this information is among the primary indicators the company uses as a basis for evaluating company performance, allocating resources, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for diluted earnings per share prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product development, divestiture of the company's medical imaging business, the company's productivity transformation initiative, and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, competitive product development, pricing controls and pressures (including changes in rules and practices of managed care groups and in
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Chemists at Indiana University Bloomington have described ... fashion, a development with potential value for the ... transistors and photovoltaic cells. , Their paper, "Anion-Induced ... Solids and 2D Self-Assembled Crystals," has been published ... of the Royal Society of Chemistry. It is ...
(Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
(Date:7/31/2014)... July 31, 2014 According to ... "Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, ... - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - ... 2013 - 2019," the global electrodes market for medical ... and is estimated to reach a market worth USD ...
(Date:7/31/2014)... July 31, 2014 Senomyx , ... company using proprietary taste science technologies to discover, ... food, beverage, and ingredient supply industries, today reported ... Company ended the second quarter with $33.6 million ... "During the past quarter Senomyx achieved another ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Seamless Performance Between GeneChip Scanner 3000 and the ... , ... Instrument System is the most advanced microarray analysis platform available and ... processes have enabled Affymetrix to produce expression probe arrays with greater consistency ...
... , Gang Li a , Savvas Damaskinos a ... a Biomedical Photometrics Inc., A12-550 Parkside ... b Dept. of Biology, Wilfrid Laurier University, 75 University Ave. ... , ABSTRACT , ...
... , L.Pereira, 1 M.Woodruff, 1 P.Deland, 2 ... , ... CA,USA , 3 Astra Zeneca R&D, Charnwood,UK , ... performance of various diode array detectors in the analysis of trace related substances of a ...
Cached Biology Technology:The New Affymetrix GeneChip Scanner 3000 2The New Affymetrix GeneChip Scanner 3000 3The New Affymetrix GeneChip Scanner 3000 4The New Affymetrix GeneChip Scanner 3000 5The New Affymetrix GeneChip Scanner 3000 6The New Affymetrix GeneChip Scanner 3000 7The New Affymetrix GeneChip Scanner 3000 8The New Affymetrix GeneChip Scanner 3000 9The New Affymetrix GeneChip Scanner 3000 10The New Affymetrix GeneChip Scanner 3000 11The New Affymetrix GeneChip Scanner 3000 12The New Affymetrix GeneChip Scanner 3000 13The New Affymetrix GeneChip Scanner 3000 14The New Affymetrix GeneChip Scanner 3000 15A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 2A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 3A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 4A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 5A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 6A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 7A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 8A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 9A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 10A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 11A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 12A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 13A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 14A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 15A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 16A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 17A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 18A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 19A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 20A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 21A new wide field-of-view confocal imaging system and its applications in drug discovery and pathology 22
(Date:7/31/2014)... Census Bureau, Latinos are the largest minority group in ... Approximately one-third of Latinos are obese and are 1.2 ... Whites. , NYU College of Nursing student researcher ... identify the factors that contribute to this problem by ... on food patterns in Latina women recently published in ...
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... from Spain, France, and the U.S. has discovered ... oldest definitive member of the tribe Omaliini that ... and description were made possible through the use ... which allows the detailed study of otherwise invisible ... described in the journal Annals of the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... Research has awarded a five-year, $7.5 million grant to a ... project is to study birds, insects and bats in order ... fly in unpredictable conditions such as zooming through dense ... to fly in open spaces or in very controlled environments," ...
... Spanish . U.S. Department of Agriculture ... first time that several species of Aspergillus niger ... and peanuts as endophytes. The researchers also showed that, ... a molecular procedure they developed, USDA Agricultural Research Service ...
... The National Institute of General Medical Sciences (NIGMS) has ... Yeshiva University a five-year, $30 million grant to study ... proteins. "Determining the structures of proteins is the ... processes as well as in disease pathways," says principal ...
Cached Biology News:UW leading $7.5 million study of animal flight and aerial vehicles 2Black aspergilli species responsible for infecting corn identified 2Einstein receives $30 million to study protein form and function 2Einstein receives $30 million to study protein form and function 3Einstein receives $30 million to study protein form and function 4
... The Light Diagnostics Universal Amplicon ... for use in the qualitative ... generated by in vitro ... use only; not to be ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... complete ready-to-use reagents for the isolation of ... formulated for the isolation of genomic DNA ... formulated for the isolation of genomic DNA ... Reagents can be used for restriction endonuclease ...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: